文献速递消化系统肿瘤妇科肿瘤

肿瘤与胚系配对检测用于林奇综合征:为诊断流程带来明确性

Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic Process.
PubMed 文献 · J Clin Oncol · 2019-01-31

该研究回顾性分析了702例结直肠癌和子宫内膜癌患者接受林奇综合征基因配对肿瘤/胚系检测的结果。在无既往胚系检测的错配修复缺陷结直肠癌和子宫内膜癌患者中,76.1%的结果对林奇综合征诊断有信息价值,有既往胚系检测者为60.8%。配对检测在无既往胚系检测组中识别出24.8%的林奇综合征胚系突变,在有既往胚系检测组中识别出9.5%。

要点

  • 配对肿瘤/胚系检测在无既往胚系检测的错配修复缺陷结直肠癌和子宫内膜癌患者中,76.1%的结果对林奇综合征诊断有信息价值。
  • 有既往胚系检测的患者中,60.8%的结果对林奇综合征诊断有信息价值。
  • 排除MLH1启动子高甲基化和胚系突变后,各组中约50%的错配修复缺陷肿瘤存在双等位基因体细胞失活。

核心结论

  • 配对检测在无既往林奇综合征胚系检测和有过既往检测的患者中,分别有76%和61%的错配修复缺陷肿瘤找到了原因。
  • 研究结果支持将肿瘤测序以及全面的林奇综合征胚系检测纳入林奇综合征检测流程。
  • 配对检测为林奇综合征提供了完整、便捷且诊断分辨率高的评估。

研究设计与样本

  • 回顾性分析了临床诊断实验室中连续接受林奇综合征基因配对肿瘤/胚系分析的结直肠癌和子宫内膜癌患者,共702例。
  • 根据既往肿瘤筛查和胚系检测结果将患者分为五组,并描述各组结果。
  • 根据医嘱进行微卫星不稳定性检测、MLH1启动子高甲基化检测以及其他基因的胚系检测。

主要发现

  • 在无既往胚系检测的错配修复缺陷结直肠癌和子宫内膜癌患者中,76.1%的结果对林奇综合征诊断有信息价值。
  • 在有既往胚系检测的错配修复缺陷结直肠癌和子宫内膜癌患者中,60.8%的结果对林奇综合征诊断有信息价值。
  • 在无既往胚系检测组中,24.8%的患者识别出林奇综合征胚系突变。
  • 在有既往胚系检测组中,9.5%的患者识别出林奇综合征胚系突变,其中4例与既往肿瘤筛查结果不一致。
  • 排除MLH1启动子高甲基化和胚系突变后,各组中约50%的错配修复缺陷肿瘤存在双等位基因体细胞失活。

关键数值与推荐

  • 无既往胚系检测的错配修复缺陷结直肠癌和子宫内膜癌患者中,76.1%的结果对林奇综合征诊断有信息价值。
  • 有既往胚系检测的错配修复缺陷结直肠癌和子宫内膜癌患者中,60.8%的结果对林奇综合征诊断有信息价值。
  • 无既往胚系检测组中林奇综合征胚系突变检出率为24.8%。
  • 有既往胚系检测组中林奇综合征胚系突变检出率为9.5%,其中4例与既往肿瘤筛查结果不一致。
  • 排除MLH1启动子高甲基化和胚系突变后,各组中约50%的错配修复缺陷肿瘤存在双等位基因体细胞失活。

临床怎么用

  • 研究结果支持将肿瘤测序以及全面的林奇综合征胚系检测纳入林奇综合征检测流程。
  • 配对检测为林奇综合征提供了完整、便捷且诊断分辨率高的评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The current diagnostic testing algorithm for Lynch syndrome (LS) is complex and often involves multiple follow-up germline and somatic tests. We aimed to describe the results of paired tumor/germline testing performed on a large cohort of patients with colorectal cancer (CRC) and endometrial cancer (EC) to better determine the utility of this novel testing methodology. MATERIALS AND METHODS: We retrospectively reviewed a consecutive series of patients with CRC and EC undergoing paired tumor/germline analysis of the LS genes at a clinical diagnostic laboratory (N = 702). Microsatellite instability, MLH1 promoter hypermethylation, and germline testing of additional genes were performed if ordered. Patients were assigned to one of five groups on the basis of prior tumor screening and germline testing outcomes. Results for each group are described. RESULTS: Overall results were informative regarding an LS diagnosis for 76.1% and 60.8% of patients with mismatch-repair-deficient (MMRd) CRC and EC without and with prior germline testing, respectively. LS germline mutations were identified in 24.8% of patients in the group without prior germline testing, and interestingly, in 9.5% of patients with previous germline testing; four of these were discordant with prior tumor screening. Upon excluding patients with MLH1 promoter hypermethylation and germline mutations, biallelic somatic inactivation was seen in approximately 50% of patients with MMRd tumors across groups. CONCLUSION: Paired testing identified a cause for MMRd tumors in 76% and 61% of patients without and with prior LS germline testing, respectively. Findings support inclusion of tumor sequencing as well as comprehensive LS germline testing in the LS testing algorithm. Paired testing offers a complete, convenient evaluation for LS with high diagnostic resolution.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Salvador MU, Truelson MRF, Mason C, et al. Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic Process. J Clin Oncol. 2019. PMID: 30702970. doi:10.1200/JCO.18.00696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。